Spinal Cord Neoplasms: Clinical Trials

19 trials for Spinal Cord Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 5 terminated, 2 recruiting, 1 withdrawn. 19 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 119Completed 11, Terminated 5, Recruiting 2, Withdrawn 1
Phase 23Completed 1, Recruiting 1, Terminated 1

Follow Spinal Cord Neoplasms: new trials by email Literature Review of Spinal Cord Neoplasms trials Research Report on Spinal Cord Neoplasms

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
NEO100 - Pediatric Tumor of CNS, Pediatric Tumor of Brain
Phase 1RecruitingNeonc Technologies, Inc.122026-09-082026-09-15
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
RRx-001, Temozolomide, Irinotecan - Brain Tumor, Recurrent, Brain Tumor, Pediatric
Phase 1TerminatedEpicentRx, Inc.22023-01-262024-10-31
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Pembrolizumab, Stereotactic Radiation Therapy, Surgical Resection - Glioblastoma Multiforme
Phase 1 / Phase 2RecruitingChirag G. Patil102021-12-092026-09-21
Intra-arterial Chemotherapy for Spinal Metastases
Melphalan (intra-arterial infusion) - Spinal Diseases, Spinal Metastases
Phase 1CompletedWeill Medical College of Cornell University122012-04-012020-08-03
Beta-Tricalcium Phosphate Bone Graft in Treating Patients Undergoing Surgery For Metastatic Spine Cancer
musculoskeletal complications management/prevention, bone graft, quality-of-life assessment - Adult Spinal Cord Neoplasm, Spinal Bone Metastases
Phase 1TerminatedUniversity of Southern California12011-06-012014-02-06
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
VEGF inhibitor PTC299 - Brain and Central Nervous System Tumors
Phase 1CompletedPediatric Brain Tumor Consortium282010-11-012015-05-04
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Phase 1TerminatedNational Cancer Institute (NCI)1292010-03-012014-11-05
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
vorinostat, temozolomide, diagnostic laboratory biomarker analysis - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Phase 1CompletedNational Cancer Institute (NCI)272010-02-012013-05-03
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
veliparib, temozolomide, pharmacological study - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor
Phase 1CompletedNational Cancer Institute (NCI)312009-07-012014-07-09
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
carboplatin, dasatinib, etoposide phosphate - Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Phase 1 / Phase 2TerminatedCity of Hope Medical Center72008-09-102026-11-04
MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer
MK-0752 - Brain and Central Nervous System Tumors
Phase 1TerminatedPediatric Brain Tumor Consortium332008-07-012012-03-06
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
talotrexin, chemotherapy - Brain and Central Nervous System Tumors, Leukemia
Phase 1WithdrawnChildren's Oncology Group2007-02-012014-08-08
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
ispinesib, laboratory biomarker analysis, pharmacological study - Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor
Phase 1CompletedNational Cancer Institute (NCI)302006-06-012013-01-16
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Cediranib Maleate - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor
Phase 1CompletedNational Cancer Institute (NCI)552006-03-012016-03-07
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
valproic acid - Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Phase 1CompletedChildren's Oncology Group262005-05-012014-08-07
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
Erlotinib hydrochloride - Brain and Central Nervous System Tumors
Phase 1 / Phase 2CompletedSt. Jude Children's Research Hospital622005-03-012015-12-04
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
romidepsin - Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor
Phase 1CompletedNational Cancer Institute (NCI)302002-09-012013-01-16
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
lonafarnib - Brain and Central Nervous System Tumors
Phase 1CompletedPediatric Brain Tumor Consortium532002-01-012009-10-14
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors
filgrastim, carboplatin, cisplatin - Brain Tumors, Central Nervous System Tumors
Phase 1CompletedChildren's Oncology Group941998-03-012014-03-28

Narrower conditions

Astrocytoma (14)  ·  Familial ependymoma (12)  ·  Medulloblastoma (12)  ·  Optic Nerve Glioma (12)  ·  Central Nervous System Neoplasms (11)  ·  Choroid Plexus Neoplasms (10)  ·  Oligodendroglioma (9)  ·  Rhabdoid Tumor (8)  ·  Burkitt Lymphoma (4)  ·  Dendritic Cell Sarcoma, Interdigitating (4)  ·  Brain Neoplasms (3)  ·  Glioma (3)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Recurrence (3)

Broader conditions

Central Nervous System Diseases (19)  ·  Neoplasms by Site (19)  ·  Nervous System Diseases (19)  ·  Nervous System Neoplasms (19)  ·  Spinal Cord Diseases (19)  ·  Neoplasms (18)  ·  Neoplasms by Histologic Type (16)  ·  Neoplasms, Germ Cell and Embryonal (16)  ·  Neoplasms, Glandular and Epithelial (16)  ·  Neoplasms, Nerve Tissue (16)  ·  Neoplasms, Neuroepithelial (16)  ·  Neuroectodermal Tumors (16)  ·  Brain Diseases (13)  ·  Glioma (13)  ·  Neuroectodermal Tumors, Primitive (13)

Interventions

Temozolomide (3)  ·  Carboplatin (2)  ·  etoposide phosphate (2)  ·  2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1)  ·  3-(4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid (1)  ·  Blotting, Western (1)  ·  Bone Transplantation (1)  ·  CK0238273 (1)  ·  Calcium Dobesilate (1)  ·  Cisplatin (1)  ·  Cyclophosphamide (1)  ·  Dasatinib (1)  ·  Dexamethasone (1)  ·  Drug Therapy (1)  ·  Erlotinib Hydrochloride (1)

Sponsors

National Cancer Institute (NCI) (6)  ·  Children's Oncology Group (3)  ·  Pediatric Brain Tumor Consortium (3)  ·  Chirag G. Patil (1)  ·  City of Hope Medical Center (1)  ·  EpicentRx, Inc. (1)  ·  Neonc Technologies, Inc. (1)  ·  St. Jude Children's Research Hospital (1)  ·  University of Southern California (1)  ·  Weill Medical College of Cornell University (1)

Countries

United States (18)  ·  Canada (4)  ·  Australia (1)

Top investigators

Alberto Broniscer, MD (1)  ·  Athos Patsalides (1)  ·  Bruce H. Cohen, MD (1)  ·  Bryan Oronsky, MD (1)  ·  Chirag G Patil, MD, MS (1)  ·  Heidi V. Russell, MD (1)  ·  Jack M. Su, MD (1)  ·  Jack Su (1)  ·  James Croop, MD, PhD (1)  ·  Josh Neman, PhD (1)  ·  Judith K. Sato, MD (1)  ·  Mark Kieran (1)  ·  Mark W. Kieran, MD, PhD (1)  ·  Maryam Fouladi (1)  ·  Maryam Fouladi, MD (1)

Results publications

PMID 17634493, PMID 21115653, PMID 23554030

NIH funding

U01CA081457 (4), U01CA097452 (4), P30CA033572 (1), R21CA256421 (1)